Abstracts tagged "Late-Breaking 2018"

Abstract Number: L14 • 2018 ACR/ARHP Annual Meeting
Top-Line Results of a Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of a Reversible B Cell Inhibitor, XmAb®5871, in Systemic Lupus Erythematosus (SLE)
Joan T. Merrill¹, Joshua June², Fotios Koumpouras³, Wambui Machua⁴, Mohammad Faisal Khan⁵, Anca Askanase⁶, Arezou Khosroshahi⁷, Saira Sheikh⁸, Paul A. Foster⁹ and Debra J. Zack⁹, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Joshua June, DO, Lansing, MI, ³Internal Medicine, Rheumatology, Yale University School of Medicine, New Haven, CT, ⁴Internal Medicine, Piedmont Atlanta Hospital, Atlanta, GA, ⁵Arthritis & Rheumatology Center of Oklahoma, PLLC, Oklahoma City, OK, ⁶Director, Columbia University Lupus Center, Columbia University Medical Center, Bronx, NY, ⁷Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁸Medicine, University of North Carolina, Chapel Hill, NC, ⁹Xencor, Inc., San Diego, CA
Background/Purpose: XmAb5871 is a humanized anti-CD19 antibody Fc-engineered for increased affinity to FcgRIIb. Co-ligation of CD19 and FcgRIIb inhibits B lineage cells key to SLE…
Abstract Number: L19 • 2018 ACR/ARHP Annual Meeting
Transcutaneous Electrical Nerve Stimulation (TENS) Reduces Pain and Fatigue and Improves Disease Impact in Women with Fibromyalgia: A Randomized Controlled Trial
Leslie Crofford¹, Dana Daily², Carol Vance³, Ruth Chimenti², Ericka Merriwether⁴, Miriam Bridget Zimmerman⁵, Jonathan Williams⁶, Meena Golchha⁶, Li Alemo Munters⁷, Katharine Geasland³, Barbara Rakel⁸ and Kathleen Sluka², ¹Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ²Physical Therapy, University of Iowa, Iowa City, IA, ³University of Iowa, Iowa City, IA, ⁴Physical Therapy, New York University, New York, NY, ⁵Public Health, University of Iowa, Iowa City, IA, ⁶Vanderbilt University Medical Center, Nashville, TN, ⁷Karolinska Institutet, Stockholm, Sweden, ⁸Nursing, University of Iowa, Iowa City, IA
Background/Purpose: Fibromyalgia (FM) is a chronic pain condition associated with pain and fatigue, especially during physical activity. Treatments designed to modulate central pain pathways to…
Abstract Number: L20 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Subcutaneous Tanezumab for the Treatment of Osteoarthritis of the Hip or Knee
Thomas J. Schnitzer¹, Richard Easton², Shirley Pang³, Dennis Levinson⁴, Glenn Pixton⁵, Lars Viktrup⁶, Isabelle Davignon⁷, Mark T. Brown⁷, Kenneth M. Verburg⁷ and Christine R. West⁷, ¹Northwestern University, Chicago, IL, ²Michigan Orthopaedic & Spine Surgeons, Rochester Hills, MI, ³St. Jude Medical Center, Fullerton, CA, ⁴Chicago Clinical Research Institute, Chicago, IL, ⁵Pfizer, Inc., Morrisville, NC, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer, Inc., Groton, CT
Background/Purpose: Tanezumab is a humanized mAb that blocks nerve growth factor (NGF) and is in clinical development for chronic pain treatment. Tanezumab administered intravenously has…
Abstract Number: L01 • 2018 ACR/ARHP Annual Meeting
New Cardiovascular Events in Patients with Gout Treated with Xanthine-Oxidase Inhibitors: An Inception Cohort Analysis
Neus Quilis¹, Laura Ranieri², Jose Sanchez-Paya² and Mariano Andrés², ¹Hospital Universitario del Vinalopó, Elche, Spain, ²Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain
Background/Purpose: The recent CARES trial findings have contributed to the controversy around the development of cardiovascular (CV) events in gouty patients using febuxostat (FBX). In…
Abstract Number: L02 • 2018 ACR/ARHP Annual Meeting
Study of Tofacitinib in Refractory Dermatomyositis (STIR): An Open Label Pilot Study in Refractory Dermatomyositis
Julie J. Paik¹, Jemima Albayda², Eleni Tiniakou³, Andrew Koenig⁴ and Lisa Christopher-Stine⁵, ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Pfizer Inc, Collegeville, PA, ⁵Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Dermatomyositis (DM) is an idiopathic inflammatory myopathy that primarily affects the muscle and skin. In refractory disease, it is common to fail 2 or…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].